194 related articles for article (PubMed ID: 37919843)
1. Adding tiotropium or long-acting β2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization.
Hanania NA; Settipane RA; Khoury S; Shaikh A; Dotiwala Z; Casciano J; Foggs MB
Allergy Asthma Proc; 2023 Nov; 44(6):413-421. PubMed ID: 37919843
[No Abstract] [Full Text] [Related]
2. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.
Kew KM; Dahri K
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011721. PubMed ID: 26798035
[TBL] [Abstract][Full Text] [Related]
3. Add-on tiotropium versus step-up inhaled corticosteroid plus long-acting beta-2-agonist in real-world patients with asthma.
Chipps B; Mosnaim G; Mathur SK; Shaikh A; Khoury S; Gopalan G; Palli SR; Lamerato L; Casciano J; Dotiwala Z; Settipane R
Allergy Asthma Proc; 2020 Jul; 41(4):248-255. PubMed ID: 32414426
[No Abstract] [Full Text] [Related]
4. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma.
Kew KM; Evans DJ; Allison DE; Boyter AC
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011438. PubMed ID: 26031392
[TBL] [Abstract][Full Text] [Related]
5. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database.
Quint JK; Montonen J; Esposito DB; He X; Koerner L; Wallace L; de la Hoz A; Miravitlles M
Adv Ther; 2021 May; 38(5):2249-2270. PubMed ID: 33721209
[TBL] [Abstract][Full Text] [Related]
7. EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS.
Buhl R; Dreher M; Mattiucci-Guehlke M; Emerson-Stadler R; Eckhardt S; Taube C; Vogelmeier CF
Adv Ther; 2023 Jul; 40(7):3263-3278. PubMed ID: 37256536
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
[No Abstract] [Full Text] [Related]
9. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826
[TBL] [Abstract][Full Text] [Related]
10. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
[TBL] [Abstract][Full Text] [Related]
11. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; Mahendran M; Hahn B
BMC Pulm Med; 2021 Jul; 21(1):253. PubMed ID: 34332555
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
Suissa S; Dell'Aniello S; Ernst P
Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort.
Busch R; Han MK; Bowler RP; Dransfield MT; Wells JM; Regan EA; Hersh CP;
BMC Pulm Med; 2016 Feb; 16():28. PubMed ID: 26861867
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
15. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
Oba Y; Keeney E; Ghatehorde N; Dias S
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
[TBL] [Abstract][Full Text] [Related]
16. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids.
Liao PA; Pan SW; Chen CY; Deng CY; Dong YH
Int J Chron Obstruct Pulmon Dis; 2023; 18():553-563. PubMed ID: 37069844
[TBL] [Abstract][Full Text] [Related]
17. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
18. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242
[TBL] [Abstract][Full Text] [Related]
19. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma.
Evans DJ; Kew KM; Anderson DE; Boyter AC
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD011437. PubMed ID: 26196545
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
